why does a biotech choose to do a reverse merger?

A biotech company may choose to undergo a reverse merger for several reasons: 1. **Liquidity and Capital Access**: Reverse mergers provide a path to liquidity for current investors and offer access to capital in the public markets. This can be particularly attractive for biotech companies that are looking to fund ongoing research and development, clinical trials, or commercialization efforts. 2. **Efficient Public Market Entry**: It can be an efficient way to enter the public markets, especially for biotech companies that have not yet met the listing requirements of exchanges like Nasdaq or NYSE. The newly public company’s valuation in a reverse merger has less dependence on market conditions typically present in the traditional IPO window. 3. **Strategic Rationale**: It can be a strategic move to combine with another company to leverage the strengths of the combined entity, such as shared resources, expertise, or market reach. Biotech companies should weigh the potential benefits against the drawbacks, such as dilution of existing shares, potential legal or contractual issues with the shell company, and the need to prove market demand for the new entity.